Winst gevend schreef op 13 november 2023 21:11:
.
Orchard Therapeutics outlook for the remainder of 2023.
BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE)
Orchard Therapeutics has outlined the following key milestones expected for the remainder of 2023:
Advance the company’s other pre-clinical programs,
which includes OTL-204 in the progranulin form of FTD and
OTL-105 partnered with and funded by Pharming Group N.V. in hereditary angioedema (HAE).
Zou ook onderhand eens tijd worden.